allergies

GSK ESMO
Biotech

GSK pays $2.2B to buy Rapt for food allergy challenger to Xolair

GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E antibody to protect against food allergy reactions.
James Waldron Jan 20, 2026 4:37am
Compressor inhaler with childs mask and pocket device for asthmatics on background of table

Vaccine protects mice from allergic reactions for a year

Apr 17, 2025 1:04pm
decision path change of plans arrows business decision

BMS backs out of Dupixent fight, axing asset despite phase 3 win

Feb 7, 2025 6:26am
compass map direction find trail north

Rapt pays $35M for challenger to Novartis, Roche drug

Dec 23, 2024 8:10am
Microscope image of a nematode

Holoclara wriggles into ph. 1, sets sights on immune disease

Dec 18, 2024 9:05am
peanuts

Food allergy biotech DBV is running out of cash

Mar 8, 2024 10:30am